How Long Until Bankruptcy...

Discussion in 'Lexicon Pharmaceuticals' started by anonymous, Jul 26, 2019 at 6:32 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Place your one dollar bets please.
     

  2. anonymous

    anonymous Guest

    wowza.... at one time Sands hyped Lex would be worth billions...now less than 200mil
     
  3. anonymous

    anonymous Guest

    its math. $130M cash on hand, $30M burn per quarter, so 4-5 quarters. In the meantime, get ready for cuts, headcount, bonuses, salaries, etc.

    Good luck
     
  4. anonymous

    anonymous Guest

    did Lex ever have to repay the state of TX for lack of job creattion? If not, isn’t that socialism?
     
  5. anonymous

    anonymous Guest

    It is insane how incompetent medical is to have lost sanofi deal and royally messed up xermelo positioning and trials. If anyone ever employs Pablo or Kiernan again they are fucking idiots bigger than those two.
     
  6. anonymous

    anonymous Guest

    $103 million in cash and burning quickly. Bold move would be to get rid of everyone except for the people you need To file for T2D. Find a buyer for Xermelo to buy you some time. Or, do what you are doing and die a slow death. But your management is still “ pleased” and “encouraged” with Q2 results.
     
  7. anonymous

    anonymous Guest

    the only thing left competent in this company is the sales force that is treated like absolute SHIT. The incompetent remains in leadership where , power, and ego remain in the way of making competent and decisions with integrity and thoughtfulness. Idiots.....And continue to believe that 98% turnover isn’t a problem.....the only thing that hasn’t left is leadership.
     
  8. anonymous

    anonymous Guest

    We gone - put a fork in us
     
  9. anonymous

    anonymous Guest

    We gone- to Popeyes yo. Pass me a wing bro!
     
  10. anonymous

    anonymous Guest

    First the ‘drug’ was selective then it was a dual acting...then research was tossed...then all in for clinical....then.... drip....drip
    Knock outs to knocked down... the story of LXRX. One hype too many
     
  11. anonymous

    anonymous Guest

    All of this defeat could NOT have happened to better people! HAHA! Good luck with your retirement Coates and the Gang.
     
  12. anonymous

    anonymous Guest

    so sad for those that saw and still see the potential in Xermelo. The arrogance and pride in leadership has only hurt patients. So glad I’m out of There...
     
  13. anonymous

    anonymous Guest

    even with Sanofi paying it won't be enough to propel the 'drug' to be first line therapy. IMHO if it gets approval for type 1 it will come with restrictions... the oncology drug is not a market driver and what else do they have? they rolled the dice with the dual acting wonder drug and so far looking like snake eyes. perhaps they need to trim the executive suite to save some cash.. BTW what is Zambrowicz doing back as a consultant? somebody sorry for him?
     
  14. anonymous

    anonymous Guest

    What does Lexicon and a Popeye Chicken Sandwich have in common? They both will be gone soon.
     
  15. anonymous

    anonymous Guest

    so they got some cash from Sanofi but will it allow them to finish the clinicals and get approved? IMHO no
    too much outstanding debt and a product on the market will horrible sales - too bad TX doesn't ask for their money back while there's still money to get. LexiCON promises but fails to complete. With no R and little D why is NJ still around? Too many people afraid of moving to HQ of a dying company?
     
  16. anonymous

    anonymous Guest

    LXRX has 103,000,000 plus sanofi handed you 208,000,000 and another 60,000,000 coming that funds you for 2 years. a lot if insider trading is happening recently and a few trials ended could be some good news coming. that said i dont work at LXRX just an investor speculating.
     
  17. anonymous

    anonymous Guest

    just forget it: the money will be spent quickly to finalize ongoing phase III studies from sanofi. The results will be sufficient to get another me-too sglt-2 inhibitor which must be produced and marketed after approval by some other company. Reps will have to convince doctors to prescribe 400 mg pills instead 5 mg or 10 mg pills from competitors, thats all, lol
     
  18. anonymous

    anonymous Guest

    you make that sound like a drag, even at worst case scenario if you can capture even 5% of this market lexicon will roll in dough... plus a lot of doctors like trying new technology
     
  19. anonymous

    anonymous Guest

    Launching a drug for diabetes is an incredibly expensive endeavor, Lexicon doesn't have the money.
     
  20. anonymous

    anonymous Guest

    . Still clueless!